Literature DB >> 12407676

Aggregate data meta-analysis with time-to-event outcomes.

Paula R Williamson1, Catrin Tudur Smith, Jane L Hutton, Anthony G Marson.   

Abstract

In a meta-analysis of randomized controlled trials with time-to-event outcomes, an aggregate data approach may be required for some or all included studies. Variation in the reporting of survival analyses in journals suggests that no single method for extracting the log(hazard ratio) estimate will suffice. Methods are described which improve upon a previously proposed method for estimating the log(HR) from survival curves. These methods extend to life-tables. In the situation where the treatment effect varies over time and the trials in the meta-analysis have different lengths of follow-up, heterogeneity may be evident. In order to assess whether the hazard ratio changes with time, several tests are proposed and compared. A cohort study comparing life expectancy of males and females with cerebral palsy and a systematic review of five trials comparing two anti-epileptic drugs, carbamazepine and sodium valproate, are used for illustration. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407676     DOI: 10.1002/sim.1303

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  203 in total

1.  Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Maria Sudell; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-06-24

2.  Prognostic role of D-dimer in patients with lung cancer: a meta-analysis.

Authors:  Xuelei Ma; Yanyan Li; Jing Zhang; Jingwen Huang; Lei Liu
Journal:  Tumour Biol       Date:  2013-10-10

3.  EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.

Authors:  Wei-Dong Shen; Hong-Lin Chen; Peng-Fei Liu
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

4.  High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients.

Authors:  Dedong Cao; Huilin Xu; Ximing Xu; Tao Guo; Wei Ge
Journal:  Oncoimmunology       Date:  2019-06-16       Impact factor: 8.110

Review 5.  Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-07-31

Review 6.  A meta-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma.

Authors:  Lorenzo A Orci; Jeremy Meyer; Christophe Combescure; Leo Bühler; Thierry Berney; Philippe Morel; Christian Toso
Journal:  HPB (Oxford)       Date:  2015-04-23       Impact factor: 3.647

Review 7.  Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.

Authors:  Sarah Lacny; Todd Wilson; Fiona Clement; Derek J Roberts; Peter D Faris; William A Ghali; Deborah A Marshall
Journal:  Clin Orthop Relat Res       Date:  2015-11       Impact factor: 4.176

Review 8.  3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  Li-Qun Zou; Bing-Lan Zhang; Qing Chang; Fu-Ping Zhu; Yan-Yan Li; Yu-Quan Wei; Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial.

Authors:  Beth S Woods; Neil Hawkins; David A Scott
Journal:  BMC Med Res Methodol       Date:  2010-06-10       Impact factor: 4.615

10.  Systematically missing confounders in individual participant data meta-analysis of observational cohort studies.

Authors:  Dan Jackson; Ian White; J B Kostis; A C Wilson; A R Folsom; K Wu; L Chambless; M Benderly; U Goldbourt; J Willeit; S Kiechl; J W G Yarnell; P M Sweetnam; P C Elwood; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; F Haverkate; M P M de Maat; S G Thompson; F G R Fowkes; A J Lee; F B Smith; V Salomaa; K Harald; V Rasi; E Vahtera; P Jousilahti; R D'Agostino; W B Kannel; P W F Wilson; G Tofler; D Levy; R Marchioli; F Valagussa; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; P Cremer; D Nagel; J D Curb; B Rodriguez; K Yano; J T Salonen; K Nyyssönen; T-P Tuomainen; B Hedblad; G Engström; G Berglund; H Loewel; W Koenig; H W Hense; T W Meade; J A Cooper; B De Stavola; C Knottenbelt; G J Miller; J A Cooper; K A Bauer; R D Rosenberg; S Sato; A Kitamura; Y Naito; H Iso; V Salomaa; K Harald; V Rasi; E Vahtera; P Jousilahti; T Palosuo; P Ducimetiere; P Amouyel; D Arveiler; A E Evans; J Ferrieres; I Juhan-Vague; A Bingham; H Schulte; G Assmann; B Cantin; B Lamarche; J-P Despres; G R Dagenais; H Tunstall-Pedoe; G D O Lowe; M Woodward; Y Ben-Shlomo; G Davey Smith; V Palmieri; J L Yeh; T W Meade; A Rudnicka; P Brennan; C Knottenbelt; J A Cooper; P Ridker; F Rodeghiero; A Tosetto; J Shepherd; G D O Lowe; I Ford; M Robertson; E Brunner; M Shipley; E J M Feskens; E Di Angelantonio; S Kaptoge; S Lewington; G D O Lowe; N Sarwar; S G Thompson; M Walker; S Watson; I R White; A M Wood; J Danesh
Journal:  Stat Med       Date:  2009-04-15       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.